The July 2014, Vol. 140, Issue 1 of Toxicological Sciences is now available online. To have the email Table of Contents (eTOC) alerts delivered to you as well as Advance Access notification of the latest papers and research in Toxicological Sciences as soon as they are accepted and posted to the website, please register online.
The paper selected for the Editor's Highlight in this issue is An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity by Laura Cove-Smith, Neil Woodhouse, Adam Hargreaves, Jason Kirk, Susan Smith, Sally A. Price, Melanie Galvin, Catherine J. Betts, Simon Brocklehurst, Alison Backen, John Radford, Kim Linton, Ruth A. Roberts, Matthias Schmitt, Caroline Dive, Jonathan D. Tugwood, Paul D. Hockings, and Howard R. Mellor. Editor–in–Chief Gary W. Miller and Associate Editor Lu Cai state that "Chemotherapeutics are the epitome of the medical double-edged sword. These agents must be sufficiently toxic to eradicate cancerous cells, but, in doing so, non-target tissues are often damaged. One prime example is the damage to the heart tissue after treatment with anthracyclines, such as doxorubicin. Damage to cardiac tissue during treatment leads to an increased rate of heart failure in cancer survivors. As such, it is important to better understand the structural and functional sequelae of treatment on the myocardium. Cove-Smith, Woodhouse, and coworkers employed a battery of cardiac measures along with sophisticated multi-modal cardiac magnetic resonance imaging (CMR) to reveal adverse cardiac consequences after doxorubicin treatment. Key findings include early functional deficits as measured by CMR, as well as subcellular myofibrillar damage and mitochondrial degeneration that occurred well before overt cardiac myocyte degeneration."
The mission of Toxicological Sciences, the official journal of the Society of Toxicology, is to publish the most influential research in the the field of toxicology.